RecruitingPhase 3NCT07280585

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Sponsor

University of Cologne

Enrollment

420 participants

Start Date

Dec 16, 2025

Study Type

INTERVENTIONAL

Conditions

Polycystic Kidney, Autosomal Dominant

Summary

Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dapagliflozin 10 mg and a drug called Matching Placebo for people with polycystic kidney, autosomal dominant. The study is currently recruiting participants at 27 locations. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDapagliflozin 10 mg

Participants receive 10 mg of Dapagliflozin orally once daily for 36 months.

DRUGMatching Placebo

Participants receive a matching placebo orally once daily for 36 months.

Locations(30)

Vorarlberger Krankenhaus-Betriebsgesellschaft

Feldkirch, Austria

Medizinische Universitaet Innsbruck

Innsbruck, Austria

Robert Bosch Gesellschaft für Medizinische Forschung mbH

Stuttgart, Baden-Wurttemberg, Germany

Klinikum Nürnberg

Nuremberg, Bavaria, Germany

Universitaetsklinikum Aachen AöR

Aachen, Germany

Charite Universitaetsmedizin Berlin KöR

Berlin, Germany

Universitätsklinikum Köln

Cologne, Germany

Klinikum Dortmund gGmbH

Dortmund, Germany

Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR

Dresden, Germany

Universitaetsklinikum Duesseldorf AöR

Düsseldorf, Germany

Goethe University Frankfurt

Frankfurt, Germany

Medical Center - University of Freiburg

Freiburg im Breisgau, Germany

Universitaetsmedizin Goettingen

Göttingen, Germany

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

Medizinische Hochschule Hannover

Hanover, Germany

Zentrum Fuer Nieren Hochdruck Und Stoffwechselerkrankungen

Hanover, Germany

Universitaetsklinikum Heidelberg AöR

Heidelberg, Germany

Universitaetsklinikum Jena KöR

Jena, Germany

Universitaetsklinikum Schleswig-Holstein AöR

Kiel, Germany

Universitaet Leipzig

Leipzig, Germany

Universitaetsklinikum Schleswig-Holstein AöR

Lübeck, Germany

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Mainz, Germany

Klinikum der Technischen Universitaet Muenchen

München, Germany

LMU Klinikum Muenchen AöR

München, Germany

Klinikum Der Landeshauptstadt Stuttgart gKAöR

Stuttgart, Germany

Universitair Medisch Centrum Groningen

Groningen, Netherlands

Leids Universitair Medisch Centrum

Leiden, Netherlands

Erasmus Universitair Medisch Centrum Rotterdam

Rotterdam, Netherlands

Fundacio Hospital Universitari Vall D'Hebron Institut De Recerca

Barcelona, Spain

Fundacio Puigvert

Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07280585